
Next-Generation Gynecological Cancer Diagnostics Market by Components (Consumables, Instruments, Software), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR)), Indication, End User - Global Forecast 2024-2030
Description
Next-Generation Gynecological Cancer Diagnostics Market by Components (Consumables, Instruments, Software), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR)), Indication, End User - Global Forecast 2024-2030
The Next-Generation Gynecological Cancer Diagnostics Market size was estimated at USD 2.13 billion in 2023 and expected to reach USD 2.32 billion in 2024, at a CAGR 10.49% to reach USD 4.29 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Gynecological Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Gynecological Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Next-Generation Gynecological Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Becton, Dickinson and Company, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Fulgent Genetics, Inc., GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Interpace Diagnostics, LLC, Janssen Pharmaceuticals, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Lucence Diagnostics Pte Ltd, Medtronic plc, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., Novartis AG, QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Next-Generation Gynecological Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Components
Consumables
Instruments
Software
Technology
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Indication
Cervical Cancer
Ovarian Cancer
Uterine Cancer
End User
Academic & Research Institutes
Diagnostic Laboratories
Hospitals & Ambulatory Centers
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Next-Generation Gynecological Cancer Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Gynecological Cancer Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Next-Generation Gynecological Cancer Diagnostics Market?
4. What is the market share of the leading vendors in the Next-Generation Gynecological Cancer Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Next-Generation Gynecological Cancer Diagnostics Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Next-Generation Gynecological Cancer Diagnostics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidences of next-generation gynecological cancer cases
- 5.1.1.2. Inclination towards early diagnosis and treatment of diseases
- 5.1.1.3. Utilization of novel markers and genetic markers
- 5.1.2. Restraints
- 5.1.2.1. High cost associated with next generation gynecological cancer diagnostics
- 5.1.3. Opportunities
- 5.1.3.1. Emerging trend of telemedicine and remote monitoring
- 5.1.3.2. Growing number of screening programs and medical tourism
- 5.1.4. Challenges
- 5.1.4.1. Complexity in manufacturing of next generation gynecological cancer diagnostics tests
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Next-Generation Gynecological Cancer Diagnostics Market, by Components
- 6.1. Introduction
- 6.2. Consumables
- 6.3. Instruments
- 6.4. Software
- 7. Next-Generation Gynecological Cancer Diagnostics Market, by Technology
- 7.1. Introduction
- 7.2. Next-Generation Sequencing (NGS)
- 7.3. Polymerase Chain Reaction (PCR)
- 8. Next-Generation Gynecological Cancer Diagnostics Market, by Indication
- 8.1. Introduction
- 8.2. Cervical Cancer
- 8.3. Ovarian Cancer
- 8.4. Uterine Cancer
- 9. Next-Generation Gynecological Cancer Diagnostics Market, by End User
- 9.1. Introduction
- 9.2. Academic & Research Institutes
- 9.3. Diagnostic Laboratories
- 9.4. Hospitals & Ambulatory Centers
- 10. Americas Next-Generation Gynecological Cancer Diagnostics Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Agilent Technologies, Inc.
- 14.1.3. ARUP Laboratories
- 14.1.4. Becton, Dickinson and Company
- 14.1.5. BGI Genomics Co., Ltd.
- 14.1.6. Bio-Rad Laboratories, Inc.
- 14.1.7. Centogene N.V.
- 14.1.8. Danaher Corporation
- 14.1.9. Epic Sciences Inc.
- 14.1.10. Exact Sciences Corporation
- 14.1.11. F. Hoffmann-La Roche Ltd.
- 14.1.12. Fujifilm Holdings Corporation
- 14.1.13. Fulgent Genetics, Inc.
- 14.1.14. GE HealthCare Technologies, Inc.
- 14.1.15. Hologic, Inc.
- 14.1.16. Illumina, Inc.
- 14.1.17. Interpace Diagnostics, LLC
- 14.1.18. Janssen Pharmaceuticals, Inc.
- 14.1.19. Konica Minolta, Inc.
- 14.1.20. Koninklijke Philips N.V.
- 14.1.21. Lucence Diagnostics Pte Ltd
- 14.1.22. Medtronic plc
- 14.1.23. Merck KGaA
- 14.1.24. Myriad Genetics, Inc.
- 14.1.25. Natera, Inc.
- 14.1.26. Novartis AG
- 14.1.27. QIAGEN N.V.
- 14.1.28. Siemens Healthineers AG
- 14.1.29. Thermo Fisher Scientific Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
- FIGURE 2. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET DYNAMICS
- FIGURE 7. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
- FIGURE 8. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
- FIGURE 10. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 12. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
- FIGURE 14. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.